Edition:
India

Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy


Wednesday, 16 Aug 2017 

Aug 16 (Reuters) - Fate Therapeutics Inc :Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy.Fate Therapeutics Inc - patent covering use of prostaglandins as viral transduction enhancers for genetic modification of cd34hematopoietic cells​.Fate Therapeutics Inc - ‍patent expires in 2029, is owned by Indiana University research and technology corporand is licensed exclusively to co. 

Company Quote

21.37
-1.13 -5.02%
19 Jul 2019